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1. Introduction 
It has been shown recently that Cyclic adenosine 
3’,5’-monophosphate is involved in the control of 
hepatic enzyme activity [ 1,2] . The cyclic nucleotide 
is thought to be the mediator of the induction of 
tyrosine aminotransferase (TAT) by glucagon [2] and 
of serine dehydratase by glucagon and amino acids 
[ 1 ] , previously shown to be also good inducers of 
TAT [3]. The enhancement of TAT activity by di- 
butyryl cyclic AMP (dbcAMP) has been shown to re- 
present de novo enzyme synthesis both in vivo [4] 
and in organ culture [2]. It has alsobeen reported 
recently that dbcAMP stimulates the incorporation 
of 3H-uridine into RNA in isolated rat liver nuclei 
[51. 
clr-Amanitin [6, 71 is a specific inhibitor of extra- 
nucleolar RNA polymerase in vifro [8, 91 . In viva, 
the toxin inhibits the incorporation into whole 
nuclear RNA [lo] _ Inhibition of the hydrocortisone 
induction of rat liver TAT has been obtained with 
a-amanitin and has been used a evidence for a require- 
ment for new RNA synthesis in the induction pro- 
cess [ll]. 
To gain a better understanding of the mechanisms 
of TAT induction, it seemed of interest to study the 
effect of a-amanitin and of actinomycin D on the in- 
duction by dbcAMP, and to compare the time courses 
of enzymatic induction by amino acids, hydrocorti- 
sone and dbcA.MP. 
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2. Materials and methods 
N6 ,02’-Dibutyryl cyclic AMP was purchased from 
Schwarz BioResearch. Hydrocortisone was obtained 
from Mann. Reagents used for the enzyme assays 
were products of Sigma. cw-Amanitin was kindly sup- 
plied by Pr.Th. Wieland of the Max-Planck Institute, 
Heidelberg, and actinomycin D was a generous gift 
of Dr. W. Dorian of Merck, Sharp and Dohme, Ltd., 
Canada. 
Rats adrenalectomized three to five days before 
use receivedl0.9% NaCl as drinking water and were 
fasted 18 hr before the beginning of the experiments. The 
amino acid mixture was identical to the one previous- 
ly used [3] and was given through a stomach tube. 
At the times indicated, the rats were sacrificed, 
the liver perfused with cold saline, removed and 
homogenized in 4 volumes of ice-cold buffer A (0.020 
M Tris-HCl, pH 7.5,0.1 M KCl, 0.01 M:MgCl,, 0.005 
M mercaptoethanol) for TAT determination, or in 
0.02 M sodium phosphate buffer @H 7.0) containing 
0.15 M KC1 for tryptophan pyrrolase (TP) determina- 
tion. Enzyme activities of the 100,000 g supernatant 
were measured and expressed as described [3]. Pro- 
tein was measured by the method of Lowry et al. 
[ 121. Statistical analysis was performed as described 
[31. 
3. Results 
The time course of stimulation of TAT activity by 
different inducers can give useful information on the 
mechanisms involved. Fig. 1 shows that significant in- 
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Fig. 1. Time course of induction of TAT activity by hydro- 
cortisone, amino acids and dbcAMP. Adrenalectomized male 
rats (250 to 300 9) were divided into groups of 4 to 6 ani- 
mals and received at time zero the following treatments: in- 
traperitoneai (i.p.) injection of hydrocortisone (3 mg/lOO g, 
B.W.) -; i.p. injection of dbcAMP (2 mg/lOO g, B.W.) 
l - - - - l ; tube feeding of a mixture of amino acids as de 
scribed under Materials and methods.- ; and i.p. injection 
of 0.9% NaCl c---o. At the indicated times, animals were 
sacrificed and TAT activity was measured in the 100,000 g 
supematant. Means and SEM are shown on the graph. pHPP: 
p-hydroxy-phenyl-pyruvate. 
crease of enzymatic activity is first measured 2 hr 
after hydrocortisone injection as observed previously 
in rat liver, both in vtio [ 131, and in vitro [ 141. 
Feeding a mixture of amino acids leads to a signifi- 
cant (P <.O.OS) stimulation of TAT activity 1 hr after 
treatment and a progressive rise of activity during the 
following hour (fig. 1). A significant (P < 0.0 1) in- 
crease of TAT activityis observed 1 hr after injection 
of dbcAMP and the level remains unchanged through- 
out the next hour (fig. 1). It should be noticed that 
the extent of stimulation reached 2 hr after treatment 
with either amino acids or dbcAMP is about 60% of 
that obtained after hydrocortisone. We could not 
detect any stimulation of tryptophan pyrrolase (TP) 
activity after treatment with dbcAMP. Fig. 2 shows 
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Fig. 2. Effect of actinomycin D on basal and dbcAMP-induced 
TAT activity. Adrenalectomized male rats (250 to 300 g) were 
divided into 5 groups of 5 to 7 animals. The animals of one 
control group were killed at time zero while the others re 
ceived the following intraperitoneal injections; NaClO.9% at 
time zero - -; dbcAMP (2 mg/lOO g, B.W.) at time zero 
-; actinomycin D (0.1 mg/lOO g, B.W.) 30 min before 
time zero 6-d; actinomycin D (0.1 mg/lOO g, B.W.) 30 
min before the injection of dbcAMP at time zero -. Two 
hours after the last injection, the animals were sacrificed and 
liver TAT activity was measured in the 100,000 g supernatant, 
as described under Materials and methods. Means and SEM are 
shown on the graph. 
that actinomycin D (0.1 mgjlO0 g, B.W.) injected 30 
min before dbcAMP completely inhibits the marked 
rise of TAT activity produced by dbcAMP. Such 
treatment is without any significant effect on the 
basal level of enzymatic activity, in agreement with 
previous reports [3, 131. In fig. 3, it can be seen that 
cr-amanitin (0.1 mg/ 100 g, B.W.), given 1 hr before 
the cyclic nucleotide, leads to a complete inhibition 
of the induction process. TAT activity measured 3 hr 
after the injection of ol-amanitin was depressed 
(P < 0.05) to 62% of the control level. 
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4. Discussion 
The:different magnitude and time courses of stimul- 
ation of TAT activity in rat liver by hydrocortisone, 
ammo acids and dbcAMP suggest at least two different 
mechanisms of action, one for hydrocortisone and at 
least one for dbcAMP and amino acids. It has been 
suggested that a mixture of amino acids [ 1 ] and tryp- 
tophan alone [ 151 stimulate respectively serine dehy- 
dratase and TAT activities with cyclic AMP acting as 
a mediator. We should expect, then, that the action of 
amino acids and of cyclic AMP would be identical on 
different hepatic enzymes. However, a mixture of 
amino acids and tryptophan alone enhance both TAT 
and TP activities in rat liver [3], while dbcAMP 
stimulates only TAT activity without affecting the 
level of TP activity [4]. These data indicate that 
amino acids and dbcAMP control TAT activity by 
different mechanisms. Coupled with the evidence al- 
ready obtained for hydrocortisone, insulin and cyclic 
AMP [2, 161, amino acids would be a fourth mechan- 
ism controlling TAT activity in rat liver. 
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The inhibition by actinomycin D (fig. 2) of the 
stimulator-y effect of the cyclic nucleotide suggests 
that RNA synthesis is required for the induction pro- 
cess. A similar inhibitory effect of actinomycin D on 
the dbcAMP-induced stimulation of TAT activity [2] 
and on the effect of glucagon [ 171 which acts through 
cyclic AMP [ 181 has been reported. Since actinomycin 
D has been reported to affect enzyme degradation 
[19] and to exert other effects besides inhibition of 
DNA-dependent RNA synthesis [20,21], the 
stringent requirement of RNA synthesis for the in- 
duction process, already suggested by our results ob- 
tained with actinomycin D, is strengthened by our 
similar findings with cr-amanitin, another inhibitor of 
RNA synthesis [lo] . As for the induction by hydro- 
cortisone [ 1 l] , these data suggest hat new RNA syn- 
thesis is an essential ink in the stimulation of TAT 
activity by dbcAh!P. The absence of any detectable 
effect of dbcAMP on total RNA synthesis [2] does 
not exclude the possibility of a specific stimulation 
by the cyclic nucleotide of a small RNA fraction 
responsible for the induction process. 
Fig. 3. Effect of o-amanitin on basal and dbcAMP-induced 
TAT activity. Adrenalectomized male rats (90 to 140 g) were 
divided into 5 groups of 6 to 7 animals. The animals of one 
control group were killed at time zero while the others re 
ceived the following intrapetitoneal injections: NaClO.9% at 
time zero O---O; dbcAMP (2 md100 g, B.W.) at time zero 
-; a-amanitin (0.1 mg/lOO g, B.W.) 1 hr before time 
zero -; o-amanitin (0.1 mg/lOO g, B.W.) 1 hr before the 
injection of dbcAMP at time zero A----+ 2 hr after the last 
injection, the animals were sacrificed and liver TAT activity 
was measured in the 100.000 g mpernatant, as described 
under Materials and methods. Means and SEM are shown on 
the graph. 
gradation and that TAT messenger RNA (mRNA) is 
stable under those conditions [ 13, 191, one would 
expect an increase of TAT activity after treatment 
with dbcAMP in the presence of a-amanitin, the 
stimulation resulting from increased translation of 
the preformed mRNA. This type of response has 
been observed with insulin and actinomycin D [23]. 
However, no important stimulation of TAT activity 
by dbcAh4P in the presence of either cu-amanitin or 
actinomycin D is observed under our experimental 
conditions. 
Apost-transcriptional site of action has been sug- If cu-amanitin does not interfere with TAT degrada- 
gested for the effect of dbcAMP on rat liver TAT tion, a half-life of approximately 3 hr can be calcul- 
[ 161 and adenohypophyseal protein synthesis [22] . ated for the enzyme activity in the presence of the 
Assuming that cw-amanitin does not enhance TAT de- toxin alone (fig. 3). This value agrees with previous 
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measurements [16,241 although higher [25] and 
lower [26] values have been reported. Assuming that 
no side effects of the toxin are involved, the half-life 
of TAT mRNA would be less than 1 hr. With measure- 
ments based on the ability of the tissue to synthesize 
TAT after treatment with actinomycin D, a value be- 
tween 2 to 3 hr for the half-life of TAT template has 
been obtained [ 191. 
If, on one hand, TAT mRNA is stable, if its con- 
centration cannot be enhanced by dbcAMP [ 161 and 
if RNA synthesis is required for the induction by 
cyclic AMP, one must postulate the existence of an 
unstable “RNA-protein” intermediate playing an es- 
sential role in the mediation of the effect of cyclic 
AMP at the translational level such as proposed for 
glucocorticoid action [27]. If, on the other hand, the 
half-life of the TAT template is short, the population 
of TAT mRNA could be reduced to such a low level 
in the presence of a-amanitin that a stimulation at the 
translational level by dbcAMP could not be detected. 
Alternatively, a direct stimulation of TAT mRNA syn- 
thesis would also explain the present findings. Until 
precise measurements of TAT mRNA synthesis and 
degradation are made, one must leave open the pos-s- 
sibility that cyclic AMP could act at more than one 
level in the regulation of TAT activity. 
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